Fig. 1: CONSORT flow and study design.

a CONSORT flow diagram summarizing patient selection and inclusion. A total of 35 patients were assessed for eligibility; six declined participation, and two were excluded for other reasons. Of the 27 included patients, three patients withdrew consent, and one patient was non-evaluable due to CAR T-cell production failure. This resulted in 23 evaluable patients with the following cohort distribution: cohort 1 (n = 7), 2 (n = 8), and 3 (n = 8). b Schematic of the study design visualizing the trajectory for all the 3 cohorts.